Psyros Diagnostics
Prototyping of a novel single-molecule-counting point-of-care system to expedite the 0-1 hour algorithm for high-sensitivity troponin testing
- Funding £99,400
- Competition Competition 17 - Urgent and Emergency Care
- Competition Date Autumn 2020
- Local AHSN Kent Surrey Sussex AHSN
- Website www.psyros.com
- Key Contact Dr Steve Ross
- Status In Development
- Pathways Cardiovascular
-
Technology In-vitro Diagnostics
Existing bedside troponin tests are insufficient for ruling out a heart attack. Psyros have developed a completely novel detection method allowing performance of high sensitivity troponin testing, within minutes, at the bedside, enabling retesting at 1 hour and faster diagnosis.
Patients presenting to A&E with chest pain are triaged using a blood test for troponin. Existing bedside troponin tests are insufficient to enable use of the 0/1h algorithm, recommended to expedite diagnosis and treatment or rule-out.
Psyros are developing a rapid, affordable, ultra-sensitive point-of-care (POC) system, to fulfil the unmet need for bedside high sensitivity troponin measurement. Our simple proprietary method enables single-molecule counting in a digital manner. Binding events generate dark spots in a fluorescent background that can be counted individually using simple optical methods. This digital approach is essential to overcome signal-to-noise limitations, allowing enhanced sensitivity. It is readily adaptable to a small footprint POC system. This will facilitate widespread adoption of the 0/1h protocol across the NHS.
Comments are closed.